Literature DB >> 16423045

The delivery of an antigen from the endocytic compartment into the cytosol for cross-presentation is restricted to early immature dendritic cells.

Chie Hotta1, Haruka Fujimaki, Masahiro Yoshinari, Masatoshi Nakazawa, Mutsuhiko Minami.   

Abstract

Dendritic cells (DCs) are the only antigen-presenting cell population having a cross-presentation capacity. For cross-presentation, however, the intracellular antigen-processing pathway and its regulatory mechanism have not been defined. Here we report the differences in cross-presentation ability among murine bone marrow-derived immature DC, early immature day8-DC and late immature day10-DC, and fully mature day10 + lipopolysaccharide DC. Day8-DCs and day10-DCs show an immature phenotypic profile but are different in morphology. Day8-DCs can internalize an abundant volume of exogenous soluble ovalbumin (OVA) and result in cross-presentation. In contrast, day10-DCs are not able to cross-present, although they maintain efficient macropinocytosis. Exogenously internalized OVA antigens are stored in the endocytic compartments. The endocytic compartments are temporarily maintained at mildly acidic pH in day8-DCs and are rapidly acidified in day10-DCs after uptake of antigens. We show that OVA antigens accumulated in the endocytic compartments move into the cytosol in day8-DCs but do not in day10-DCs. NH(4)Cl-treatment, which neutralizes the acidic endocytic compartments and/or delays endosomal maturation, restores day10-DCs for transport the stored OVA antigens from the endocytic compartments into the cytosol. Diphenyleneiodonium chloride-treatment, which acidifies the endocytic compartments, decreases an amount of transported OVA antigen into the cytosol in day8-DCs. These data indicate that only the early immature stage of DC interferes with endosomal maturation, even after uptake of exogenous antigens, and then transports the antigens into the cytosol.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423045      PMCID: PMC1782205          DOI: 10.1111/j.1365-2567.2005.02270.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

Review 1.  Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.

Authors:  B W Robinson; R A Lake; D J Nelson; B A Scott; A L Marzo
Journal:  Immunol Cell Biol       Date:  1999-12       Impact factor: 5.126

2.  Rac is required for constitutive macropinocytosis by dendritic cells but does not control its downregulation.

Authors:  M A West; A R Prescott; E L Eskelinen; A J Ridley; C Watts
Journal:  Curr Biol       Date:  2000-07-13       Impact factor: 10.834

3.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.

Authors:  A Rodriguez; A Regnault; M Kleijmeer; P Ricciardi-Castagnoli; S Amigorena
Journal:  Nat Cell Biol       Date:  1999-10       Impact factor: 28.824

4.  CD36 is differentially expressed by CD8+ splenic dendritic cells but is not required for cross-presentation in vivo.

Authors:  Gabrielle T Belz; David Vremec; Maria Febbraio; Lynn Corcoran; Ken Shortman; Francis R Carbone; William R Heath
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

5.  Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling.

Authors:  Michele A West; Robert P A Wallin; Stephen P Matthews; Henrik G Svensson; Rossana Zaru; Hans-Gustaf Ljunggren; Alan R Prescott; Colin Watts
Journal:  Science       Date:  2004-08-20       Impact factor: 47.728

Review 6.  Lysosome-endosome fusion and lysosome biogenesis.

Authors:  J P Luzio; B A Rous; N A Bright; P R Pryor; B M Mullock; R C Piper
Journal:  J Cell Sci       Date:  2000-05       Impact factor: 5.285

7.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

8.  The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli.

Authors:  K Inaba; S Turley; T Iyoda; F Yamaide; S Shimoyama; C Reis e Sousa; R N Germain; I Mellman; R M Steinman
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

9.  Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells.

Authors:  C Driessen; R A Bryant; A M Lennon-Duménil; J A Villadangos; P W Bryant; G P Shi; H A Chapman; H L Ploegh
Journal:  J Cell Biol       Date:  1999-11-15       Impact factor: 10.539

10.  Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation.

Authors:  Lelia Delamarre; Hilda Holcombe; Ira Mellman
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

View more
  21 in total

1.  Modifying Dendritic Cell Activation with Plasmonic Nano Vectors.

Authors:  Kieng Bao Vang; Ingrid Safina; Emilie Darrigues; Dmitry Nedosekin; Zeid A Nima; Waqar Majeed; Fumiya Watanabe; Ganesh Kannarpady; Rajshekhar A Kore; Daniel Casciano; Vladimir P Zharov; Robert J Griffin; Ruud P M Dings; Alexandru S Biris
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

2.  Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.

Authors:  Bruno Garulli; Maria G Stillitano; Vincenzo Barnaba; Maria R Castrucci
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

Review 3.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

4.  The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I-peptide complex formation.

Authors:  Yuanyuan Ding; Zhenhong Guo; Yiqi Liu; Xia Li; Qian Zhang; Xiongfei Xu; Yan Gu; Yi Zhang; Dezhi Zhao; Xuetao Cao
Journal:  Nat Immunol       Date:  2016-08-22       Impact factor: 25.606

5.  Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation.

Authors:  Nicole L Yates; Martha A Alexander-Miller
Journal:  Virology       Date:  2006-10-20       Impact factor: 3.616

Review 6.  The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation.

Authors:  Jeff E Grotzke; Debrup Sengupta; Qiao Lu; Peter Cresswell
Journal:  Curr Opin Immunol       Date:  2017-05-18       Impact factor: 7.486

7.  H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.

Authors:  Tao Qin; Yinyan Yin; Lulu Huang; Qinghua Yu; Qian Yang
Journal:  Clin Vaccine Immunol       Date:  2015-02-11

8.  Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.

Authors:  Marlène Brandes; Katharina Willimann; Gilles Bioley; Nicole Lévy; Matthias Eberl; Ming Luo; Robert Tampé; Frédéric Lévy; Pedro Romero; Bernhard Moser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.

Authors:  Olivier Renaudet; Gargi Dasgupta; Ilham Bettahi; Alda Shi; Anthony B Nesburn; Pascal Dumy; Lbachir BenMohamed
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

10.  A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells.

Authors:  Laurence Bougnères; Julie Helft; Sangeeta Tiwari; Pablo Vargas; Benny Hung-Junn Chang; Lawrence Chan; Laura Campisi; Gregoire Lauvau; Stephanie Hugues; Pradeep Kumar; Alice O Kamphorst; Ana-Maria Lennon Dumenil; Michel Nussenzweig; John D MacMicking; Sebastian Amigorena; Pierre Guermonprez
Journal:  Immunity       Date:  2009-08-21       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.